Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $8.67.
Several research firms recently issued reports on CHRS. Truist Financial decreased their target price on shares of Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, May 13th. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Coherus BioSciences in a research report on Friday, May 24th. Finally, Robert W. Baird decreased their target price on shares of Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating on the stock in a research report on Monday.
Get Our Latest Stock Analysis on Coherus BioSciences
Coherus BioSciences Price Performance
Coherus BioSciences (NASDAQ:CHRS – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The business had revenue of $77.06 million for the quarter, compared to the consensus estimate of $102.00 million. During the same quarter in the prior year, the company earned ($0.89) earnings per share. As a group, analysts forecast that Coherus BioSciences will post -1.14 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the business. TrinityPoint Wealth LLC purchased a new stake in shares of Coherus BioSciences during the fourth quarter valued at approximately $40,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Coherus BioSciences by 430.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,880 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 10,454 shares during the period. Baader Bank Aktiengesellschaft purchased a new stake in shares of Coherus BioSciences during the fourth quarter valued at approximately $47,000. Vontobel Holding Ltd. purchased a new stake in shares of Coherus BioSciences during the fourth quarter valued at approximately $50,000. Finally, ELCO Management Co. LLC purchased a new stake in shares of Coherus BioSciences during the third quarter valued at approximately $57,000. Hedge funds and other institutional investors own 72.82% of the company’s stock.
About Coherus BioSciences
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Featured Articles
- Five stocks we like better than Coherus BioSciences
- The 3 Best Fintech Stocks to Buy Now
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is an Earnings Surprise?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.